Survival disparities among African American (AA) patients (pts) with EGFR-mutated non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Cheng, Haiying
Hosgood, H. Dean
Ye, Qian
Sharma, Janaki Neela
Su, Christopher
Halmos, Balazs
Perez-Soler, Roman
机构：
[1] Montefiore Med Ctr, Dept Med Oncol, Albert Einstein Coll Med, Bronx, NY USA
[2] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY USA
[3] Albert Einstein Coll Med, Bronx, NY USA
[4] Montefiore Med Ctr, Albert Einstein Coll Med, New York, NY USA
[5] Montefiore Med Ctr, Bronx, NY USA
[6] Montefiore Med Ctr, Dept Med Oncol, Bronx, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.9054
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9054
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung Cancer
    Cheng, Haiying
    Hosgood, H. Dean
    Deng, Lei
    Ye, Kenny
    Su, Christopher
    Sharma, Janaki
    Yang, Yuanquan
    Halmos, Balazs
    Perez-Soler, Roman
    CLINICAL LUNG CANCER, 2020, 21 (02) : 177 - 185
  • [2] Response and survival in African American (AA) patients (pts) with non-small cell lung cancer (NSCLC) treated with erlotinib (E)
    Villaflor, V. M.
    Kanteti, R.
    Watson, S. M.
    Karrison, T.
    Vokes, E. E.
    Salgia, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Estrogen Metabolism in Patients with EGFR-Mutated and ALK-Mutated Non-Small Cell Lung Cancer (NSCLC)
    Bodor, J. N.
    Treat, J.
    Krzizike, D. D.
    Zawislak, C. L.
    Vanderveer, L.
    Yulis, M.
    Chau, A.
    Ross, E. A.
    Andrews, A. J.
    Clapper, M. L.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (02) : S18 - S19
  • [4] Plasma metabolite biomarkers for EGFR-mutated non-small cell lung cancer (NSCLC)
    Thamlikitkul, Lucksamon
    Manocheewa, Siriphan
    Limjiasahapong, Suphitcha
    Wanichthanarak, Kwanjeera
    Panya, Atikorn
    Poungvarin, Naravat
    Pomyen, Yotsawat
    Khoomrung, Sakda
    CANCER RESEARCH, 2024, 84 (06)
  • [5] Depression and Inflammation in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
    Cardona, A.
    Arrieta, O.
    Rojas, L.
    Zatarain-Barron, Z.
    Ricaurte, L.
    Ruiz-Patino, A.
    Martin, C.
    Carranza, H.
    Vargas, C.
    Otero, J.
    Corrales, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S871 - S871
  • [6] Treatment strategy of EGFR-mutated non-small cell lung cancer
    Tanaka, Fumihiro
    Yoneda, Kazue
    Takenaka, Masaru
    Kuroda, Koji
    JOURNAL OF THORACIC DISEASE, 2022, 14 (03) : 602 - 606
  • [7] Emerging drugs for EGFR-mutated non-small cell lung cancer
    Sukrithan, Vineeth
    Deng, Lei
    Barbar, Alexander
    Cheng, Haiying
    EXPERT OPINION ON EMERGING DRUGS, 2019, 24 (01) : 5 - 16
  • [8] How to Treat EGFR-Mutated Non-Small Cell Lung Cancer
    Belani, Neel
    Liang, Katherine
    Fradley, Michael
    Judd, Julia
    Borghaei, Hossein
    JACC: CARDIOONCOLOGY, 2023, 5 (04): : 542 - 545
  • [9] Safety of osimertinib in EGFR-mutated non-small cell lung cancer
    Mezquita, Laura
    Varga, Andreea
    Planchard, David
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1239 - 1248
  • [10] Systemic treatment of EGFR-mutated non-small cell lung cancer
    Czyzykowski, Rafal L.
    Wrona, Ewa K.
    Talajko, Agata
    Hasinska, Aleksandra M.
    Potemski, Piotr J.
    ONCOLOGY IN CLINICAL PRACTICE, 2024,
12345